engleski

Optimal choice of antimicrobial therapy for Pseudomonas aeruginosa urinary tract infections in outpatients

The aim of this study is to determine frequency of Pseudomonas aeruginosa urinary tract infection (UTI) in outpatient's population in South Croatia and to suggest optimal antimicrobial treatment for these patients. During 3 months long observation period, from total number of 13 158 examined urine specimens, significant bacteriuria was found in 2341 specimens. P. aeruginosa was the sixth most common isolate. It was isolated from 94 specimens (4.02%). These 94 specimens were taken from 57 different patients. Susceptibility testing was performed by disk diffusion method, and the following results were obtained: resistance to cefibuten occurred in 94.74% patients. to norfoxacin in 49.12%, to ciprofloxacin in 47.37%. to gentamicin in 42.11%, to netilmicin in 35.09%, to arnikacin in 24.56%, to ceftazidime in 3.51% and to imipenem in 1.75% patients. P. aeruginosa strains showed better susceptibility to tested parenteral antibiotics than to antibiotics for oral use which complicated treatment in outpatients. The best susceptibility was shown to irnipenem, but this drug is inappropriate for use in outpatients setting, so the best choice for treatment P. aeruginosa UTI in our outpatients is treatment with ceftazidime.

Pseudomonas ; therapy

nije evidentirano